Status:
In progress
Technology type:
Medicine
Decision:
Selected
Prioritisation programme:
Medicines evaluation
Rationale:

Review of TA972.

Process:
STA Standard
ID number:
6757

Provisional Schedule

Committee meeting:
13 January 2027
Expected publication:
13 May 2027

Project Team

Project lead
Kate Moore

Email enquiries

If you have any queries please email TACommD@nice.org.uk


External Assessment Group:
Kleijnen Systematic Reviews Ltd

Stakeholders

Companies sponsors
Plusultra (sirolimus gel)
Others
Department of Health and Social Care
 
NHS England
Patient carer groups
Beacon for Rare Diseases
 
Changing Faces
 
Gene People
 
Genetic Alliance UK
 
Let’s Face It
 
South Asian Health Foundation
 
Specialised Healthcare Alliance
 
Tuberous Sclerosis Association
Professional groups
Association of Genetic Nurses & Counsellors
 
British Association of Dermatologists
 
British Dermatological Nursing Group
 
British Geriatrics Society
 
British Society for Gene and Cell Therapy
 
British Society for Genetic Medicine
 
British Society for Paediatric and Adolescent Dermatology
 
General Medical Council
 
Neonatal and Paediatric Pharmacists Group
 
Primary Care Dermatology Society
 
Psychodermatology UK
 
Royal College of General Practitioners
 
Royal College of Nursing
 
Royal College of Paediatrics and Child Health
 
Royal College of Pathologists
 
Royal College of Physicians
 
Royal Pharmaceutical Society
 
Royal Society of Medicine
 
UK Clinical Pharmacy Association
 
UK Kidney Association
Associated public health groups
Public Health Wales
 
UK Health Security Agency
Comparator companies
None
General commentators
All Wales Therapeutics and Toxicology Centre
 
Allied Health Professionals Federation
 
Board of Community Health Councils in Wales
 
British National Formulary
 
Care Quality Commission
 
Cell and Gene Therapy Catapult
 
Department of Health - Northern Ireland
 
Great Ormond Street Hospital
 
Healthcare Improvement Scotland
 
Medicines and Healthcare products Regulatory Agency
 
National Association of Primary Care
 
National Pharmacy Association
 
NHS Confederation
 
NHS Wales Joint Commissioning Committee
 
Scottish Medicines Consortium
 
Welsh Government
Relevant research groups
British Skin Foundation
 
Cochrane Skin Group
 
Dermatrust
 
Genomics England
 
MRC Clinical Trials Unit
 
National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
10 June 2026 Invitation to participate
10 June 2026 Awaiting development. Status change linked to topic prioritisation decision being set to Selected
10 June 2026 In progress. Invitation to participate
06 May 2026 - 27 May 2026 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual